

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

Nr.	Material or product	Type of activity	Internal reference number
<b>Laboratory of HLA Diagnostic Services, subdivision of department of Immunogenetics</b>			
1	Heparin-blood	HLA-B27 confirmation by means of PCR-SSP (electrophoresis)	3068/ 3103/ 3196 in house method
2		HLA-A, -B,-C typing, by means of a cytotoxicity assay (phase contrast-or fluorescence microscopy) and/or PCR-SSP (electrophoresis) -SSO	3103/ 2079/ 0887/ 4825/ 4518 in house method 2083/ 3067/ 6346/ 6330/ 4709 equivalent to protocol manufacturer
3		HLA-DR, DQ typing, by means of a cytotoxicity assay (fluorescence microscopy) and/or PCR-SSP (electrophoresis) -SSO	3103/ 2079/ 4825/ 4518 in house method 3067/ 6346/ 6330/ 4709 equivalent to protocol manufacturer
4		HLA-DR2 typing, by means of a cytotoxicity assay ( fluorescence microscopy) and/or PCR-SSP (electrophoresis) -SSO	2079/ 3103/ 2092/ 4825/ 4518 in house method
5	Serum	Antibodies against HLA-A, -B, -C by means of a cytotoxicity test (fluorescence microscopy) xMAP technique (Luminex)	2089 in house method 5876/5880/5906 equivalent to protocol manufacturer
6	Heparin-blood	Antibodies against HLA-A, -B, -C additional testing by means of a cytotoxicity assay (fluorescence microscopy)	2444 in house method
7		HLA-DQ2 and/or HLA-DQ8 typing by means of PCR-SSP/SSO technique (electrophoresis)	3103/ 4518/ 4825 in house method 3067/ 6346/ 6330/ 4709 equivalent to protocol manufacturer
8	Blood	HLA class I and II high resolution genotyping (sequence based typing)	5470 equivalent to protocol manufacturer

This annex has been approved by:

Ir. J.C. van der Poel  
Chief Executive

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

Nr.	Material or product	Type of activity	Internal reference number
<b>Flexibel scope*</b>			
<b>Laboratory of Paternity Testing, subdivision of department of Immunogenetics</b>			
9	Blood, chorionic villi and buccal mucosa cells	DNA-isolation, amplification and typing of four multiplex systems: CTTv (CSF1PO, TH01, TPOX and vWA), FFFL (F13A01, F13B, FESFPS and LPL), SGM PLUS and Powerplex 16, Chimera, D5/FGA and Yfiler (capillary electrophoresis)	4135/5992 equivalent to protocol manufacturer
10		Sampling, identification, analysis, interpretation and reporting of paternity and other family related investigation according to the recommendations of the ISFG	4321/ 3005/ 3008/ 3011/ 5484/ 5502 in house method in accordance with ISFG: Paternity testing commission of the International Society of Forensic Genetics 2002 and  in accordance with Resolution DNA investigation paternity: Law gazette Kingdom of the Netherlands, 2008: 417

\*Within the description of these type(s) of activity, the laboratory is allowed - after validation - to change or adjust the accredited testing methods for reasons of improvement or on customers request.

Nr.	Material or Product	Type of activity	Internal reference number
<b>Laboratory of Viral Nucleic acid Diagnostic Services, subdivision of department of Viral Diagnostic Services</b>			
11	Plasma	HIV-1 RNA quantitative 'cDNA-PCR' (Real Time Fluorescence)	6572 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
12	Serum and plasma	HCV RNA quantitative 'cDNA-PCR' (Real Time Fluorescence)	6571 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
13	Plasma	HCV /HIV RNA qualitative 'PCR' (hybridisation and EIA)	3159 in house method
14	Serum and plasma	HBV DNA qualitative 'PCR' (hybridisation and EIA)	5215/ 5194 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
15	Plasma	HBV DNA quantitative 'PCR' (Real Time Fluorescence)	6570 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
16	Serum and plasma	HCV RNA Genotyping 'PCR' (Line Probe Assay)	4352 in house method
17	Blood and PBMC	HIV-1 DNA qualitative 'PCR' (hybridisation and EIA)	0919 in house method
18	Plasma	HAV-RNA assay by use of the LightCycler (Real Time Fluorescence)	5907 in house method
19		HIV-1 RNA qualitative 'PCR' (hybridisation and ELISA)	4164 in house method
20	Serum and plasma	Quantitative Parvo B19 (Real Time Fluorescence)	4768/ 5776/ 6132/ 6536 in house method
21	Plasma	HIV-1 resistance genotyping using the ViroSeq™ HIV-1 Genotyping System V2.0 Celera/Abbott	4572 in accordance with protocol manufacturer
22		Detection of HCV-RNA in mini-pools (NAT)	5924/ 5835/ 6477 equivalent to protocol manufacturer
23		Detection of HIV-RNA in mini-pools (NAT)	5924/ 5835/ 6477 equivalent to protocol manufacturer

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

Nr.	Material or product	Type of activity	Internal reference number
<b>Laboratory of Virus Serology Diagnostic Services, subdivision of department of Viral Diagnostic Services</b>			
24	Serum and plasma	Specification of HCV antibodies (Recombinant-Immunoblot)	3144 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
25		Specification of HIV 1 and 2 antibodies (Recombinant-Immunoblot)	2236 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
26		Specification of HTLV I/II antibodies (Recombinant-Immunoblot)	4373 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
27		HBsAg neutralisation assay (MEIA)	4374 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
28		Quantification of HBs antibodies by means of PLA (MEIA)	4090 in house method
29		Quantification of HAV antibodies by means of PLA (MEIA)	4090 in house method
30		Detection of IgM HAV antibodies (MEIA)	4320 in accordance with protocol manufacturer
31		Detection of HAV antibodies (MEIA)	4320/ 4089 in accordance with protocol manufacturer

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

Nr.	Material or product	Type of activity	Internal reference number
32	Serum and plasma	Detection of HBs antibodies (MEIA)	4320/ 4088 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
33		Detection of HIV p24 core-antigen (EIA)	4965 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
34		Detection of HTLV I and II antibodies (EIA)	4783 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
35		Specification of Treponema Pallidum antibodies (Recombinant-Immunoblot)	5328 in accordance with protocol manufacturer
36		Detection of antibodies with RPR card antigen for diagnostics of Syphilis (agglutination)	1367 in accordance with protocol manufacturer
37		Detection of Malaria antibodies (EIA)	5897 in accordance with protocol manufacturer
38		Detection of HBsAg (CMIA)	6099 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
39		Detection of HBs antibodies (CMIA)	6099 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
40		Detection of HBc antibodies (CMIA)	6099 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
41	Serum and plasma	Detection of IgM HBc antibodies (CMIA)	6099 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
42		Detection of HBe antibodies (CMIA)	6099 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
43		Detection of HBeAg (CMIA)	6099 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
44		Detection of HCV antibodies (CMIA)	6099 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
45		Simultaneously detection of HIV 1/2 antibodies and HIV antigen 'Combo' (CMIA)	6099 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
46		Detection of Treponema Pallidum antibodies (CMIA)	6099 in accordance with protocol manufacturer
47		Detection of HBsAg using the PRISM (ChLIA)	6204 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
48		Detection of anti-HIV using the PRISM (ChLIA)	6204 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)

**Laboratory of Erythrocyte Serology,  
subdivision of department of Immune Haematology Diagnostic Services**

49	EDTA-blood	Rhesus D, ABO blood group + screening antibodies in 30nd week pregnancy (agglutination)	0340 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
50	Blood	Analysis upon problems with ABO blood group typing (agglutination)	5007 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
51	Blood	Analysis upon problems with Rhesus D antigen typing (agglutination)	5008 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
52		Determination of the specificity of erythrocyte antibodies (particularly agglutination)	1350/ 4807/ 4809/ 4810 in accordance with protocol manufacturer
53		Investigation on transfusion related problems (particularly agglutination)	4892 in accordance with protocol manufacturer
54		Specificity of irregular erythrocyte antibodies after positive screening of antibodies in the first term of pregnancy (particularly agglutination)	4670 in house method
55		Investigation of the cause of haemolysis and auto immune haemolytic anaemia (particularly agglutination)	4862 in accordance with protocol manufacturer
56		Investigation of the cause of haemolytic disease of the Newborn (particularly agglutination)	4806 in house method
57	Clotted blood	Blood tests on regular anti-Rhesus D plasmapheresis donor (agglutination)	0716 in house method
58	Plasma	Erythrocyte antibodies in a plasma pool (agglutination)	0291 in accordance with protocol manufacturer
59	Intravenous immunoglobulin	Erythrocyte antibodies in intravenous immunoglobulin preparations (agglutination)	0292 in accordance with protocol manufacturer (European Pharmacopoeia 6.2, 07/2008:20626)
60	Factor VIII preparations	Erythrocyte antibodies in factor VIII preparations (agglutination)	0293 in accordance with protocol manufacturer (European Pharmacopoeia 5.6, 01/2007:0275)

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
61	Anti D immunoglobuline	Erythrocyte antibodies in anti D immuno globulin (agglutination)	0294 in accordance with protocol manufacturer
62	Erythrocyte suspension	Antigen control of defrosted erythrocyte for immunisation (agglutination)	0691 in accordance with protocol manufacturer
63	Plasma	Blood group genotyping using PCR	2348 in house method

**Laboratory of Blood Transfusion Technology (BTT),  
subdivision of department of Blood Cell Research**

64	Blood cell suspension (after leucocytes reduction)	Leucocyte counting for the performance of leucocyte reduction filters (fluorescence)	2190 in house method
65	Blood cell suspension	Haematological parameters on behalf of characterisation blood components a. leucocytes (Coulter impedance) b. haematocrit (centrifugation) c. haemoglobin (spectrophotometric) d. thrombocytes (Coulter impedance) e. erythrocytes (Coulter impedance)	0933/ 2192/ 5771 in house method
66		Quantification of blood gasses: pCO <sub>2</sub> , pO <sub>2</sub> en pH (selectivity electrode -> potential difference)	5670 in house method
67		Free haemoglobin content (spectrophotometric)	2192 in house method
68		Nucleotide analysis to study metabolic condition in case of quality control of stability studies (HPLC anion-exchange)	2188/ 2915 in house method
69		Enzymatic 2,3-DPG assay (spectrophotometry)	2731 in house method
70		Enzymatic ATP assay (spectrophotometry)	4143 in house method
71	Platelets suspension	Platelet activation antigen assay (FACS)	2197 in house method

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

Nr.	Material or product	Type of activity	Internal reference number
<b>Laboratory of Thrombocytes/Leucocytes Serology, subdivision of department of Immune Haematology Diagnostic Services</b>			
72	EDTA-blood and clotted blood	Platelet Immune fluorescence test 'PIFT'	1278/ 1279/ 2495 in house method
73		Granulocyte Immune fluorescence test 'GIFT'	2400 in house method
74	EDTA-blood	Glycoprotein profile (FACS)	2536 in house method
75	Blood	Lymphocyte Immune fluorescence test 'LIFT' (IF plus FACS)	2777 in house method
76		Monoclonal Antibody Immobilisation of Thrombocyte Antigens 'MAIPA' (ELISA)	1211 in house method
77		Monoclonal Antibody Solid phase Platelet Antibody Test 'MASPAT' (ELISA)	0753 in accordance with protocol manufacturer
78		Heparin induced thrombocytopeny 'HIT' (ELISA)	2513 in accordance with protocol manufacturer
79	EDTA-blood	Thrombopoietin 'TPO' (ELISA)	3451 in house method
80	Serum and plasma	Antibody-screening and antibody-specificity (MAIPA, PIFT, LIFT, GIFT, LAT, MASPAT)	3112 in house method except MASPAT= in accordance with protocol manufacturer
81	EDTA-blood and clotted blood	Transfusion-Related Acute Lung Injury ('TRALI') (GIFT, LIFT, LAT)	5209 in house method
82		Thrombocytopenia of the Newborn (MAIPA, MASPAT, LIFT en PIFT)	0752 in house method except MASPAT= in accordance with protocol manufacturer
83		Neonatal Allo Immune Neutropenia (NAINP)	2961 in house method

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
84	EDTA-blood and clotted blood	Granulocyte-specificity (IF and FACS)	5211 in house method
85	Blood	1-day MAIPA-HRP (ELISA)	6006 in house method

**Laboratory of Serology Infectious diseases,  
subdivision of department of National Screenings Laboratory Sanquin**

86	Serum and plasma	Detection of HBsAg by means of PRISM (ChLIA)	3433 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
87		Detection of HCV antibodies by means of PRISM (ChLIA)	3434 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
88		Detection of HIV 1/2 antibodies by means of PRISM (ChLIA)	3435 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
89		Detection of HTLV I/II antibodies by means of PRISM (ChLIA)	3436 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
90		Determination of anti-Parvo B19 (EIA)	5081 in accordance with protocol manufacturer
91		Determination of Total Protein (spectrophotometry)	5368 in accordance with protocol manufacturer

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

Nr.	Material or product	Type of activity	Internal reference number
<b>Laboratory of NAT Infectious diseases, subdivision of department of National Screenings Laboratory Sanquin</b>			
92	Plasma	Detection of HIV-RNA, HCV RNA and HBV DNA in Minipools with the S201 system (NAT)	6448 in accordance with protocol manufacturer (IVD Directive 98/97/EC annex II / list A)
<b>Department of Blood Coagulation</b>			
93	Citrated-plasma	Activated partial thromboplastin time (APTT)	0464 in accordance with protocol manufacturer
94		Prothrombin time (PT)	0462 in accordance with protocol manufacturer
95		Protein S total antigen	5331 in house method
96		Protein C (chromogenic)	0461 in house method
97		Activated protein C (APC) resistance	4099 in accordance with protocol manufacturer
98		Factor VIII (one-stage method)	3287 in house method
99		Von Willebrand factor (ristocetin cofactor) activity	5105 in house method
100		Antithrombin activity (chromogenic)	0447 in house method
101	Citrated-plasma	Factor IX activity (one-stage method)	6335 in house method
102	Citrated plasma and factor VIII concentrates	Factor VIII activity (chromogenic)	0460 in house method

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
103	Citrated plasma	Lupus anticoagulant/ Circulating anticoagulant	0469 in house method
104		Protein S free antigen (latex immuno assay)	4791 in house method
105	Citrated plasma and concentrates	F VII activity (one-stage)	0458 in house method
106	Citrated plasma	Protein C activity (BCS)	5755 in house method
107	EDTA Blood	Factor V Leiden mutation (1691G>A)	6551/ 3476 in house method
108		Prothrombine mutation (20210G>A)	6551/ 3476 in house method
109		MTHFR mutation (677C>T)	6551/ 3476 in house method

**Laboratory of Allergy Diagnostic Services,  
subdivision of department of Immunopathology Diagnostic Services**

110	Serum	Allergen specific IgE (RAST)	1052 in house method
111		IgA antibodies against gliadine (ELISA)	4156 in house method
112	Plasma	IgG antibodies against tetanus toxoid (RIA)	4887 in house method
113	Serum	IgG antibodies against Infliximab (Remicade) (antigen binding assay)	5539 in house method
114		IgA antibodies against tTG (ELISA)	5547 in house method
115		Infliximab level (ELISA)	5798 in house method
116		Adalimumab level (ELISA)	6574 in house method

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
117	Serum	IgG antibody against adalimumab (Humira) (antibinding assay)	6575 in house method

**Laboratory of Autoimmune Diseases,  
subdivision of department of Immunopathology Diagnostic Services**

118	Serum and plasma	Antibodies against nucleic/ cytoplasmatic antigens with Euroimmun ANA Profile 3 Euroline (IgG)	5874/ 6445 in accordance with protocol manufacturer
119	Serum	Antibodies against acetylcholine receptors (RIA)	1562 in accordance with protocol manufacturer
120	Serum and plasma	Antibodies against glomerular basal membrane (ELISA)	1610 in accordance with protocol manufacturer
121	Serum	Antibodies against TSH receptors (RIA)	4437 in accordance with protocol manufacturer
122	Serum and plasma	Antibodies against TPO (UniCAP 100) (FEIA)	5769 in accordance with protocol manufacturer
123		Antibodies against Tg (UniCAP 100) (FEIA)	5768 in accordance with protocol manufacturer
124	Serum	Antibodies against ds-DNA (FARR assay) (RIA)	1239 in house method
125		Antibodies against ds-DNA (PEG assay) (RIA)	1240 in house method
126	Serum and plasma	IgM Rf (ELISA)	0319 in house method
127		Antibodies against Endomysium (IFT)	1024 in house method
128		ANCA (IFT)	0387 in house method

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
129	Serum and plasma	ANCA (ELISA)	2945/ 6445 in house method
130	Serum	Antibodies against citrullinated fibrinogen 'ACF' (ELISA)	4970 in house method
131	Serum and plasma	Antibodies against cyclic citrullinated peptide 2 'CCP-2' by means of Unicap 100 (ELISA)	6445 in accordance with protocol manufacturer
132	Serum	Antibodies against Intrinsic Factor Recombinant (RIPA)	5281 in house method
133		Antibodies against glutamate-decarboxylase 65 (GAD65) (RIPA)	5161 in house method
134		Antibodies against islet antigen-2 (IA-2) (RIPA)	5162 in house method
135	Serum and Plasma	Antibodies against parietal cells(IFT)	1555 in house method
136		Antibodies against smooth muscle(IFT)	1556 in house method
137		Antibodies against mitochondria(IFT)	1557/ 6078 in house method
138		ANA Hep-2 Cell (IFT)	1237 in house method
139		Antibodies against soluble liver antigen (SLA/LP) (lineblott)	6078 in accordance with protocol manufacturer

**Laboratory of Immunochemistry,**  
**subdivision of department of Immunopathology Diagnostic Services**

140	Serum	IgA using the BN2 (nephelometry)	2562 in accordance with protocol manufacturer
141		IgM using the BN2 (nephelometry)	2563 in accordance with protocol manufacturer

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
142	Serum	IgG using the BN2 (nephelometry)	2564 in accordance with protocol manufacturer
143		IgG1 using the BN2 (nephelometry)	2565 in accordance with protocol manufacturer
144		IgG2 using the BN2 (nephelometry)	2566 in accordance with protocol manufacturer
145		IgG3 using the BN2 (nephelometry)	2567 in accordance with protocol manufacturer
146		IgG4 using the BN2 (nephelometry)	2568 in accordance with protocol manufacturer
147		IgA1 using the BN2 (nephelometry)	4667 in accordance with protocol manufacturer
148		IgA2 using the BN2 (nephelometry)	4668 in accordance with protocol manufacturer
149		C1q using the BN2 (nephelometry)	2580 in house method
150		C3 using the BN2 (nephelometry)	2578 in house method
151		C4 using the BN2 (nephelometry)	2579 in accordance with protocol manufacturer
152		Alpha-1-antitrypsine using the BN2 (nephelometry)	2570 in house method
153		Ceruloplasmin using the BN2 (nephelometry)	2573 in accordance with protocol manufacturer

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
154	Serum	Haptoglobin using the BN2 (nephelometry)	2591 in accordance with protocol manufacturer
155		CH50 titer (immunehaemolysis, spectrofotometry)	0562 in house method
156		Determination of M-protein (zone electrophoresis, immune fixation)	0560/ 0561 in accordance with protocol manufacturer
157		Circulating immunecomplexes 'C1q binding assay' (RIA)	0797 in house method
158	EDTA-plasma	C1-esterase-inhibitor activity (chromogene assay)	0398 in house method
159	Serum	C5 using the BN2 (nephelometry)	4693 in house method
160		Factor B using the BN2 (nephelometry)	4692 in house method
161		AP50 titer (immune hemolysis, spectrofotometry)	0720 in house method
162		Mannose Binding Lectin using Summit (EIA)	5531 in house method
163	Plasma and Serum	Antibodies against C1-esterase-inhibitor (EIA)	5839 in house method
164		C1-esterase-inhibitor-antigen (nephelometry)	2587 in accordance with protocol manufacturer

**Laboratory of Immunocytology,  
subdivision of department of Immunohaematology Experimental**

165	Blood, bone marrow, spinal fluid, pleura fluid, ascites, glands and biopts	Immunophenotyping (Immuno fluorescence)	4605 in house method
-----	--	--	-------------------------

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

<b>Nr.</b>	<b>Material or product</b>	<b>Type of activity</b>	<b>Internal reference number</b>
166	Blood, bone marrow, spinal fluid, pleura fluid, ascites, glands and biops	Real-time PCR to establish leukaemia and lymphoma specific chromosome translocations (PCR)	4603 in house method
167	Blood and leucopheresis material	Absolute number leucocytes subsets (flow cytometry)	4831 CD34 enumeration=in house method lymphocyte subsets (CD4/CD8 enumeration) = in accordance with protocol manufacturer
168	Blood	JAK2V617F mutation (PCR)	6091 in house method

**Laboratory of Red Cell Diagnostic Services,  
subdivision of department of Blood Cell Research**

169	Citrate anticoagulated whole blood	Glucose-6-phosphate dehydrogenase activity in erythrocytes (spectrophotometry)	6140 in house method
170		Glutathione reductase activity in erythrocytes (spectrophotometry)	6141 in house method
171		Pyruvate kinase activity in erythrocytes (spectrophotometry)	6142 in house method
172	Citrate or EDTA anticoagulated whole blood	Alpha-thalassemia (DNA/multiplex PCR)	6045 in house method
173		Separation of haemoglobins (cation exchange HPLC)	4301 in house method

The subdivision of the accreditation certificate for Research and Development types of activities applies to the execution of activities concerning the research restricted to and based upon accredited types of activities as described in the specification at the accreditation certificate or documented activities derived from it

**Laboratory of Blood Transfusion Technology (BTT),  
subdivision of department of Blood Cell Research**

174	Blood transfusion aids	Performance studies in blood transfusion aids	Fluorescence, potentiometry, spectrophotometry, fluid chromatography, FACS, 2933 optical measurement
-----	------------------------	---	---

of **Sanquin Blood Supply Foundation**  
**Sanquin Diagnostic Services and Sanquin Research**  
**Amsterdam**

Valid from: **22-06-2009** to **30-09-2010**

Replaces annex dated: **05-02-2009**

ALAT	= Alanine aminotransferase
ANCA	= Anti Neutrofilic Cytoplasmatic Antibodies
ATP	= Adenosine triphosphate
BN2	= Behring Nephelometer 2
BSA	= Bovine Serum Albumin
ChLIA	= Chemi Luminescence Immuno Assay
DNA	= Deoxyribo Nucleic Acid
DPG	= Di-phospho glycerate
DTT	= Dithiotreitol
EIA	= Enzyme Immuno Assay
ELISA	= Enzyme Linked Immunosorbent Assay
ENA	= Extractable nucleic antigens
FACS	= Fluorescent Activated Cell Sorter (flowcytometer)
FARR	= RIA for quantitative determination of anti-dsDNA
GIFT	= Granulocyte Immune Fluorescence Test
HAV	= Hepatitis A Virus
HBsAg	= Hepatitis B surface Antigen
HBV	= Hepatitis B Virus
HCV	= Hepatitis C Virus
HIV	= Human Immunodeficiency Virus
HLA	= Human Leucocyte Antigens
HPLC	= High Pressure Liquid Chromatography
HTLV	= Human T-cell Leukemia Virus
IB(T)	= Immunoblot (test)
IF(T)	= Immunofluorescence (test)
Ig	= Immunoglobulins
LAT	= Leucocyte Agglutination Test
LE	= Lupus Erythematodes
LIFT	= Lymphocyte Immune Fluorecence Test
MAIPA	= Monoclonal Antibody Immobilization of Platelet Antigens
MASPAT	= Monoclonal Antibody Solid Phase Platelet Antibody Test
MEIA	= Microparticle Enzyme Immuno Assay
NASBA	= Nucleic Acid Sequence Based Amplification
NAT	= Nucleic Acid amplification technology
PBMC	= Perifer Blood Mononuclear Cells
PCR	= Polymerase Chain Reaction
PEG	= Poly Ethylene Glycol
PIFT	= Platelet Immune Fluorescence Test
PLA	= Parallel-Line Assay
RAST	= Radio Allergo Sorbent Test
RIA	= Radio Immuno Assay
RIBA	= Recombinant Immuno Blot Assay
RIPA	= Radio Immuno Precipitation Assay
RPR	= Rapid Plasma Reagin
RFLP	= Restriction Fragment Length Polymorphism
SSO	= Sequence Specific Oligonucleotide
SSP	= Sequence Specific Primers
Tg	= Thyreoglobulin
TPO	= Thyroidperoxidase
TSH	= Thyroid Stimulating Hormone
TTG	= Tissue Transglutaminase